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Abstract The proto-oncoprotein Hdm2 is a member of the
RING ¢nger-type family of ubiquitin^protein ligases E3. The
RING ¢nger domain is assumed to mediate the speci¢c inter-
action of an E3 with its cognate ubiquitin-conjugating enzyme
E2, which catalyzes the covalent attachment of ubiquitin to
substrate proteins. In addition, the RING ¢nger domain of
Hdm2 is involved in Hdm2 homooligomer formation and has
the capacity to bind to RNA in a sequence-speci¢c manner.
Here we report that interaction with nucleic acids interferes
with both Hdm2/Hdm2 complex formation and auto-ubiquitina-
tion of Hdm2 in vitro. Furthermore, although binding of Hdm2
to the tumor suppressor p53 is not inhibited by nucleic acids,
Hdm2-mediated ubiquitination of p53 is signi¢cantly decreased.
Taken together, these results provide the ¢rst example of an E3
whose activity can be regulated by direct interaction with nu-
cleic acids.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Ampli¢cation of the gene encoding the proto-oncoprotein
Hdm2 (Mdm2 in mouse) has been implicated in the develop-
ment of several human tumors including sarcomas and osteo-
sarcomas [1,2]. Moreover, genetic analyses in mice demon-
strated that Mdm2 de¢cient mice are only viable in a p53
null background, indicating that Mdm2 is a functional antag-
onist of the tumor suppressor protein p53 [3]. Structurally,
Hdm2 consists of an N-terminal p53 binding domain, a cen-
tral acidic region of yet unknown function, a zinc binding
motif, and a C-terminal RING ¢nger motif. RING ¢nger
motifs are often indicative of proteins with E3 ubiquitin ligase
activity [4^6]. Indeed, Hdm2 facilitates ubiquitination and
subsequent proteasome-mediated degradation of p53 [7^11],
thereby inactivating the growth-suppressive properties of p53
[1,2,12]. In addition, Hdm2 itself is a target for ubiquitination
(‘auto-ubiquitination’) and degradation [10,11].
Members of the RING ¢nger family of E3s comprise at
least two functional domains [4^6]. One domain determines
the substrate speci¢city of the respective E3. The other do-
main, the RING ¢nger motif, mediates the interaction of the
E3 with its cognate E2 ubiquitin-conjugating enzyme, which
covalently conjugates ubiquitin to a substrate protein. Thus,
in a simpli¢ed mechanistic view, RING ¢nger E3s can be
considered as adaptor proteins bringing substrate proteins
and E2s into close proximity for E2-catalyzed ubiquitination.
Notably, the substrate interaction domain and the RING ¢n-
ger motif can be present on a single polypeptide chain, as in
the case of Hdm2, or on several distinct proteins that form an
E3 complex.
In vitro studies have shown that Hdm2 functionally inter-
acts with the human E2 UbcH5 [10,11,13]. In addition to
mediating the E2 interaction, the RING ¢nger domain of
Hdm2 is required for homooligomerization of Hdm2 and is
involved in complex formation with the Hdm2-related protein
HdmX [14,15]. Furthermore, the Hdm2 RING ¢nger domain
has the capacity to bind to RNA in a sequence-speci¢c man-
ner [16,17]. Here we show that the presence of nucleic acids
inhibits the ability of Hdm2 to target itself and p53 for ubiq-
uitination. Furthermore, nucleic acids interfere with the abil-
ity of Hdm2 to form homomeric complexes. Since nucleic
acids do not interfere with, or even slightly stimulate, the
interaction of Hdm2 with p53, these results suggest that ho-
mooligomerization is required for Hdm2 to be active as an
E3.
2. Materials and methods
2.1. Plasmids and protein expression
The constructs for in vitro translation of p53, E6-AP, and RLIM,
respectively, and the construct for bacterial expression of a gluta-
thione S-transferase fusion protein of Hdm2 were described previ-
ously [13,18,19]. For in vitro translation of Hdm2, the cDNA for
Hdm2 was cloned into the expression vector pcDNA3.1. The cDNA
encoding a C-terminally truncated Hdm2 (Hdm2vRING, encompass-
ing amino acid residues 1^423; deletion of RING ¢nger domain) was
generated by PCR-based methods and cloned into pcDNA3.1.
For in vitro ubiquitination experiments, Hdm2 was expressed as
glutathione S-transferase fusion protein in Escherichia coli DH5K.
The ubiquitin-activating enzyme E1 and E6-AP were expressed in
the baculovirus system, and the ubiquitin-conjugating enzyme
UbcH5 was expressed in E. coli BL21 as described [18,20].
2.2. In vitro ubiquitination assays
For in vitro ubiquitination, 1 Wl of rabbit reticulocyte lysate-trans-
lated 35S-labeled substrate (p53, Hdm2, E6-AP, or RLIM) was incu-
bated in the presence of 50 ng E1, 50 ng UbcH5, and 10 Wg ubiquitin
in 50 Wl volumes. For ubiquitination of p53 and Hdm2, the reaction
additionally contained bacterially expressed Hdm2 (500 ng). Ubiqui-
tination of E6-AP was performed in the additional presence of bacu-
lovirus-expressed E6-AP (50 ng). In addition, reactions contained var-
ious RNAs or DNAs as indicated (1 Wg), 25 mM Tris^HCl (pH 7.5),
100 mM NaCl, 1 mM dithiothreitol, 2 mM ATP, and 4 mM MgCl2.
After incubation at 30‡C for 2 h, total reaction mixtures were elec-
trophoresed in 10% sodium dodecyl sulfate (SDS)^polyacrylamide
gels and 35S-labeled substrates detected by £uorography.
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2.3. In vitro binding assays
Coprecipitation experiments using glutathione S-transferase fusion
proteins were performed as previously described [18]. Brie£y, 10 Wl of
rabbit reticulocyte lysate-translated 35S-labeled Hdm2 or p53 was in-
cubated with bacterially expressed glutathione S-transferase or the
Hdm2 glutathione S-transferase fusion protein in 200 Wl volumes con-
taining 0.1 mM Tris^HCl (pH 7.5), 150 mM NaCl, 1 mM dithiothrei-
tol, and 0.5% of the non-ionic detergent IGEPAL in the presence or
absence of 5 Wg of polyG or polydA at 4‡C. After 3 h, bound proteins
were puri¢ed by glutathione a⁄nity chromatography, electrophoresed
in 10% SDS^polyacrylamide gels, and 35S-labeled proteins detected by
£uorography. The ability of in vitro translated Hdm2, Hdm2vRING,
E6-AP, and RLIM to bind to polyG was determined under similar
conditions using polyG-agarose as an a⁄nity matrix.
3. Results
3.1. Nucleic acids inhibit auto-ubiquitination of Hdm2
The RING ¢nger domain of Hdm2 has been reported to
have the ability to bind to RNA in a sequence-speci¢c man-
ner, suggesting that interaction with nucleic acids may a¡ect
the E3 activity of Hdm2 [16,17]. To test this hypothesis, the
e¡ect of di¡erent homopolymeric nucleic acids on Hdm2-in-
duced ubiquitination of itself (‘auto-ubiquitination’) was de-
termined [10,11]. In vitro translated radiolabeled Hdm2 was
incubated in the presence of recombinant ubiquitin-activating
enzyme E1, recombinant UbcH5, ubiquitin, and bacterially
expressed Hdm2 under standard ubiquitination conditions
(see Section 2). This resulted in the formation of high molec-
ular weight forms of Hdm2 (Fig. 1A). Since the appearance of
these high molecular weight forms is dependent on the pres-
ence of UbcH5 and ubiquitin [21], it can be concluded that
these forms represent highly ubiquitinated species of Hdm2.
Addition of various homopolyribonucleotides (polyA, polyC,
polyG, polyA-U), tRNA (not shown), or homopolydesoxy-
ribonucleotides (polydA, polydAT) completely abolished
Hdm2 auto-ubiquitination.
Since Hdm2 was reported to bind speci¢cally to polyG but
not to other homopolyribonucleotides [16], titration experi-
ments were performed with polyG and polydA (Fig. 1B).
However, no signi¢cant di¡erence between polyG and polydA
was observed with respect to their ability to inhibit Hdm2
auto-ubiquitination, suggesting that Hdm2 binds to polyG
and polydA with similar e⁄ciency under the conditions
used. Alternatively, the nucleic acids used may not interfere
with Hdm2 auto-ubiquitination at the level of Hdm2 but
rather inhibit the activity of E1 and/or UbcH5. To address
this possibility, the e¡ect of polyG on the auto-ubiquitination
capacity of two Hdm2-unrelated E3s (E6-AP, RLIM) was
determined [19,22]. As shown in Fig. 1C,D, auto-ubiquitina-
tion of these E3s was either not inhibited (E6-AP) or even
slightly stimulated (RLIM) by polyG. Since auto-ubiquitina-
tion of both E6-AP and RLIM requires the activity of E1 and
UbcH5 [19,22], this indicates that polyG and other homopo-
ly(desoxy)ribonucleotides inhibit Hdm2 auto-ubiquitination
by directly interfering with the E3 activity of Hdm2.
The ability of Hdm2, E6-AP, and RLIM, respectively, to
bind to polyG was tested in coprecipitation experiments using
polyG-agarose as an a⁄nity matrix. As expected, Hdm2
bound to polyG (Fig. 2A) and binding of Hdm2 to polyG
was dependent on the RING ¢nger domain (Fig. 2B). Fur-
thermore, RLIM bound to polyG (Fig. 2D), whereas an in-
teraction of E6-AP with polyG was not observed under the
conditions used (Fig. 2C). Since polyG interferes with auto-
ubiquitination of Hdm2 but not with RLIM auto-ubiquitina-
tion, these data (both Hdm2 and RLIM interact with polyG)
indicate that the inhibitory e¡ect of nucleic acids is speci¢c for
Hdm2 auto-ubiquitination.
3.2. Nucleic acids interfere with Hdm2/Hdm2 interaction
Addition of bacterially expressed Hdm2 is required to ob-
serve e⁄cient ubiquitination of in vitro translated Hdm2, in-
dicating that the concentration of Hdm2 has to reach a
threshold level for auto-ubiquitination [21]. A likely explana-
Fig. 1. RNA and DNA homopolymers interfere with Hdm2 auto-
ubiquitination. One Wl of the indicated in vitro translated radiola-
beled protein (Hdm2, E6-AP, RLIM) was incubated under standard
ubiquitination conditions (see Section 2) in the absence (3) or in
the presence of di¡erent nucleic acids as indicated. After 2 h, the re-
spective reaction mixtures were analyzed by SDS^polyacrylamide gel
electrophoresis(PAGE) followed by £uorography. A: Reactions were
performed in the presence of 1 Wg of the nucleic acids indicated and
in the additional presence of bacterially expressed glutathione
S-transferase-Hdm2 fusion protein (GST-Hdm2). B: Reactions were
performed in the presence of the indicated amounts of polyG or
polydA and in the absence (3) or presence (+) of GST-Hdm2. The
reaction in the absence of GST-Hdm2 was performed in the pres-
ence of GST. C: Reactions were performed in the additional pres-
ence of baculovirus-expressed E6-AP. D: Note that the use of in vi-
tro translated RLIM is su⁄cient to observe auto-ubiquitination
activity [19]. ‘Input’ represents 1 Wl of the respective in vitro trans-
lated protein. The running positions of ubiquitinated forms of
Hdm2, E6-AP, and RLIM are indicated by an asterisk.
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tion for this observation is that auto-ubiquitination of Hdm2
occurs in trans (see Section 4) and proceeds via homooligomer
formation. Moreover, since Hdm2 forms homooligomeric
complexes via its RING ¢nger domain [14,15] and RNA binds
to the RING ¢nger (Fig. 2A,B) [16,17], a possible explanation
for the inhibitory e¡ect of nucleic acids on Hdm2 auto-ubiq-
uitination is that nucleic acid binding interferes with Hdm2/
Hdm2 interaction. Indeed, addition of polyG or polydA to
coprecipitation experiments inhibits the binding of in vitro
translated radiolabeled Hdm2 to a glutathione S-transferase-
Hdm2 fusion protein (Fig. 3A).
3.3. Nucleic acids do not interfere with binding of Hdm2 to p53
but inhibit Hdm2-mediated ubiquitination of p53
Hdm2 is best known for its role in ubiquitination and deg-
radation of p53 [1,2,7^12]. To determine the e¡ect of nucleic
acids on Hdm2-mediated ubiquitination of p53, the e¡ect of
polyG on the ability of Hdm2 to bind to p53 was investigated
next. This showed that polyG did not interfere with binding
of Hdm2 to p53 (Fig. 3B). This observation is readily ex-
plained by the fact that binding of Hdm2 to p53 is mediated
by the N-terminal region of Hdm2 and is not dependent on
the presence of the C-terminal RING ¢nger domain [1,2,12].
However, addition of nucleic acids signi¢cantly interfered
with Hdm2-mediated ubiquitination of p53 in vitro (Fig. 4),
suggesting that p53 ubiquitination requires Hdm2 oligomeri-
zation. It should be noted, however, that the C-terminal re-
gion of p53 has been implicated in the interaction with single-
stranded nucleic acids (reviewed in [23]). Thus, an alternative
but not mutually exclusive explanation for the inhibitory ef-
fect of nucleic acids is that nucleic acid-bound p53 is not as
e⁄ciently recognized as a substrate by Hdm2 as nucleic acid-
free p53. However, this hypothesis cannot be directly tested,
since the C-terminus of p53 is also required for e⁄cient
Hdm2-mediated ubiquitination of p53 in vitro [24,25].
4. Discussion
Several biochemical properties have been attributed to the
RING ¢nger domain of Hdm2 including the ability to form
homooligomers, to interact with RNA, and to function as an
E3 ubiquitin^protein ligase [9^11,14^17]. If these di¡erent
properties of Hdm2 are mechanistically linked, and, thus, af-
fect each other in a negative or positive manner has remained
unclear. In this study, we show that binding to nucleic acids
inhibits both the E3 activity of Hdm2 and the ability of Hdm2
to form homooligomeric complexes. This provides a novel
mechanism, by which Hdm2-mediated ubiquitination process-
es can be regulated.
The observation that binding to nucleic acids inhibits
Hdm2-mediated auto-ubiquitination can be explained by at
least two possibilities. Firstly, since nucleic acid binding also
interferes with Hdm2 homooligomerization (see Fig. 3A), ho-
mooligomerization may be a prerequisite for Hdm2 auto-
ubiquitination. This hypothesis is supported by the fact that
in order to observe auto-ubiquitination, Hdm2 levels need to
reach a certain threshold [21]. This indicates that Hdm2 auto-
ubiquitination occurs in trans (i.e. ubiquitination of a given
Hdm2 molecule is mediated by another Hdm2 molecule)
rather than in cis (a given Hdm2 molecule mediates its own
ubiquitination). Secondly, in analogy to other RING ¢nger
E3s [4^6], the RING ¢nger domain of Hdm2 is assumed to
mediate the interaction with its cognate E2. Thus, an alter-
native but not mutually exclusive possibility is that nucleic
acid binding interferes with the interaction of Hdm2 with its
cognate E2. This possibility cannot be experimentally ad-
dressed at present. Although UbcH5 supports auto-ubiquiti-
nation of Hdm2 and Hdm2-mediated ubiquitination of p53 in
vitro, a stable physical interaction between Hdm2 and UbcH5
has not been reported and has not been observed by us under
the conditions of a coprecipitation experiment (unpublished
observation). In any event, both mechanisms (RNA interferes
with Hdm2 homooligomerization and/or Hdm2/E2 interac-
tion) would also explain the observation that nucleic acids
inhibit Hdm2-mediated ubiquitination of p53, although nu-
Fig. 2. Binding of Hdm2 to polyG depends on the RING ¢nger do-
main. Ten Wl of in vitro translated radiolabeled Hdm2 (A),
Hdm2vRING (a C-terminally truncated Hdm2 mutant devoid of
the RING ¢nger domain) (B), E6-AP (C), or RLIM (D) were incu-
bated with polyG-agarose (polyG-agar.) or protein A-agarose (Pro-
tA-agar.) as control. The amount of proteins bound to protein
A-agarose or polyG-agarose was determined by SDS^PAGE and
£uorography. ‘Input’ represents 20% of the amount of the respective
radiolabeled protein used for coprecipitation analysis.
Fig. 3. PolyG interferes with Hdm2/Hdm2 interaction but not with
the interaction of Hdm2 with p53. Ten Wl of in vitro translated ra-
diolabeled Hdm2 (A) or p53 (B) were incubated with bacterially ex-
pressed glutathione S-transferase (GST) or a glutathione S-transfer-
ase-Hdm2 fusion protein (GST-Hdm2) in the absence or presence of
polyG or polydA as indicated (for conditions, see Section 2). The
amount of proteins bound to GST or GST-Hdm2 was determined
by SDS^PAGE and £uorography. ‘Input’ represents 20% of the
amount of the respective radiolabeled protein used for coprecipita-
tion analysis.
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cleic acids do not interfere with Hdm2/p53 complex formation
under the conditions used.
Although we did not observe signi¢cant di¡erences between
di¡erent RNA and DNA homopolymers in their ability to
inhibit the E3 activity of Hdm2, there is experimental evidence
that Hdm2 has the property to bind to certain RNAs in a
sequence-speci¢c manner [16,17]. This suggests that RNA-
mediated inhibition of the E3 activity of Hdm2 is of physio-
logical signi¢cance. To experimentally address this issue, an
Hdm2 mutant that has lost the ability to bind to nucleic acids
but is still active as an E3 should prove helpful. However, if
such a mutant can be generated is presently unclear, since
both properties (nucleic acid binding, E3 activity) depend on
the RING ¢nger domain of Hdm2. Finally, the observation
that both Hdm2 and RLIM bind to polyG may indicate that
RING ¢nger E3s in general have the ability to interact with
nucleic acids. Thus, it will be interesting to determine if the E3
activity of other RING ¢nger E3s can be modulated by nu-
cleic acids.
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Fig. 4. RNA and DNA homopolymers inhibit Hdm2-mediated
ubiquitination of p53. In vitro translated p53 was incubated in the
presence of Hdm2 under standard ubiquitination conditions (Section
2) in the absence or in the presence of 1 Wg of di¡erent nucleic
acids as indicated. After 2 h, the respective reaction mixtures were
analyzed by SDS^PAGE followed by £uorography. The running po-
sitions of ubiquitinated forms of p53 are indicated by an asterisk.
FEBS 27742 23-10-03
L.K. Linares, M. Sche¡ner/FEBS Letters 554 (2003) 73^7676
